These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 24369313)
1. T2 enhances in situ level of Foxp3+ regulatory cells and modulates inflammatory cytokines in Crohn's disease. Li G; Ren J; Wang G; Gu G; Hu D; Ren H; Hong Z; Wu X; Liu S; Li J Int Immunopharmacol; 2014 Feb; 18(2):244-8. PubMed ID: 24369313 [TBL] [Abstract][Full Text] [Related]
2. Triptolide downregulates Treg cells and the level of IL-10, TGF-β, and VEGF in melanoma-bearing mice. Liu B; Zhang H; Li J; Lu C; Chen G; Zhang G; Lu A; He X Planta Med; 2013 Oct; 79(15):1401-7. PubMed ID: 23975869 [TBL] [Abstract][Full Text] [Related]
3. Triptolide ameliorates IL-10-deficient mice colitis by mechanisms involving suppression of IL-6/STAT3 signaling pathway and down-regulation of IL-17. Li Y; Yu C; Zhu WM; Xie Y; Qi X; Li N; Li JS Mol Immunol; 2010 Sep; 47(15):2467-74. PubMed ID: 20615550 [TBL] [Abstract][Full Text] [Related]
4. Triptolide ameliorates Crohn's colitis is associated with inhibition of TLRs/NF-κB signaling pathway. Yu C; Shan T; Feng A; Li Y; Zhu W; Xie Y; Li N; Li J Fitoterapia; 2011 Jun; 82(4):709-15. PubMed ID: 21376787 [TBL] [Abstract][Full Text] [Related]
5. Increase of regulatory T cells in ileal mucosa of untreated pediatric Crohn's disease patients. Reikvam DH; Perminow G; Lyckander LG; Gran JM; Brandtzaeg P; Vatn M; Carlsen HS Scand J Gastroenterol; 2011 May; 46(5):550-60. PubMed ID: 21281255 [TBL] [Abstract][Full Text] [Related]
6. FoxP3(+)CD4(+)CD25(+) T cells with regulatory properties can be cultured from colonic mucosa of patients with Crohn's disease. Kelsen J; Agnholt J; Hoffmann HJ; Rømer JL; Hvas CL; Dahlerup JF Clin Exp Immunol; 2005 Sep; 141(3):549-57. PubMed ID: 16045746 [TBL] [Abstract][Full Text] [Related]
7. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease. Ricciardelli I; Lindley KJ; Londei M; Quaratino S Immunology; 2008 Oct; 125(2):178-83. PubMed ID: 18422560 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic effects of triptolide on interleukin-10 gene-deficient mice with colitis. Wei X; Gong J; Zhu J; Niu L; Zhu W; Li N; Li J Int Immunopharmacol; 2008 Dec; 8(13-14):1808-12. PubMed ID: 18804190 [TBL] [Abstract][Full Text] [Related]
9. Suppressive and Gut-Reparative Functions of Human Type 1 T Regulatory Cells. Cook L; Stahl M; Han X; Nazli A; MacDonald KN; Wong MQ; Tsai K; Dizzell S; Jacobson K; Bressler B; Kaushic C; Vallance BA; Steiner TS; Levings MK Gastroenterology; 2019 Dec; 157(6):1584-1598. PubMed ID: 31513797 [TBL] [Abstract][Full Text] [Related]
10. The suppressive effect of triptolide on chronic colitis and TNF-alpha/TNFR2 signal pathway in interleukin-10 deficient mice. Wei X; Gong J; Zhu J; Wang P; Li N; Zhu W; Li J Clin Immunol; 2008 Nov; 129(2):211-8. PubMed ID: 18757245 [TBL] [Abstract][Full Text] [Related]
11. IL-15 interferes with suppressive activity of intestinal regulatory T cells expanded in Celiac disease. Zanzi D; Stefanile R; Santagata S; Iaffaldano L; Iaquinto G; Giardullo N; Lania G; Vigliano I; Vera AR; Ferrara K; Auricchio S; Troncone R; Mazzarella G Am J Gastroenterol; 2011 Jul; 106(7):1308-17. PubMed ID: 21468011 [TBL] [Abstract][Full Text] [Related]
12. Expression of CD4+ forkhead box P3 (FOXP3)+ regulatory T cells in inflammatory bowel disease. Wang Y; Liu XP; Zhao ZB; Chen JH; Yu CG J Dig Dis; 2011 Aug; 12(4):286-94. PubMed ID: 21791023 [TBL] [Abstract][Full Text] [Related]
13. Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease. Saruta M; Yu QT; Fleshner PR; Mantel PY; Schmidt-Weber CB; Banham AH; Papadakis KA Clin Immunol; 2007 Dec; 125(3):281-90. PubMed ID: 17897887 [TBL] [Abstract][Full Text] [Related]
14. Triptolide promotes generation of FoxP3+ T regulatory cells in rats. Zhang G; Liu Y; Guo H; Sun Z; Zhou YH J Ethnopharmacol; 2009 Aug; 125(1):41-6. PubMed ID: 19560530 [TBL] [Abstract][Full Text] [Related]
15. Triptolide modulates T-cell inflammatory responses and ameliorates experimental autoimmune encephalomyelitis. Wang Y; Mei Y; Feng D; Xu L J Neurosci Res; 2008 Aug; 86(11):2441-9. PubMed ID: 18438925 [TBL] [Abstract][Full Text] [Related]
16. Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn's disease. Rismo R; Olsen T; Cui G; Paulssen EJ; Christiansen I; Johnsen K; Florholmen J; Goll R Scand J Gastroenterol; 2013 Mar; 48(3):311-9. PubMed ID: 23302000 [TBL] [Abstract][Full Text] [Related]
17. Triptolide ameliorates ileocolonic anastomosis inflammation in IL-10 deficient mice by mechanism involving suppression of miR-155/SHIP-1 signaling pathway. Wu R; Li Y; Guo Z; Gong J; Zhu W; Li N; Li J Mol Immunol; 2013 Dec; 56(4):340-6. PubMed ID: 23911388 [TBL] [Abstract][Full Text] [Related]
18. Over-expression of forkhead box P3 and its association with receptor activator of nuclear factor-kappa B ligand, interleukin (IL) -17, IL-10 and transforming growth factor-beta during the progression of chronic periodontitis. Dutzan N; Gamonal J; Silva A; Sanz M; Vernal R J Clin Periodontol; 2009 May; 36(5):396-403. PubMed ID: 19419438 [TBL] [Abstract][Full Text] [Related]
19. Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease. Juanola O; Moratalla A; Gutiérrez A; Sempere L; Zapater P; Giménez P; Almenta I; Peiró G; González-Navajas JM; Such JF; Francés R J Gastroenterol; 2015 Jul; 50(7):758-68. PubMed ID: 25500977 [TBL] [Abstract][Full Text] [Related]
20. FOXP3+ regulatory T-cell counts correlate with histological response in Crohn's colitis treated with infliximab. Sloan S; Maxwell P; Salto-Tellez M; Loughrey MB Pathol Int; 2014 Dec; 64(12):624-7. PubMed ID: 25354875 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]